Clinical Therapeutics

Clinical Therapeutics 由 Elsevier Inc. 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Health Systems, Economic Evaluations, Quality of Life、Diabetes Treatment and Management、Pharmaceutical Economics and Policy 等主题的论文，这 3 个主题约占 20.3%，主导子领域为 Economics and Econometrics。（根据 OpenAlex 主题统计与中科院分区数据生成）

Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drugs, biologicals, and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research and development. In addition, Clinical Therapeutics features updates on specific topics collated by expert Topic Editors and Guest Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.Published articles range from pivotal studies exploring new chemical entities in large, multicenter trials to those exploring repurposing of marketed agents. Additionally, pilot study reports that assess drug safety and tolerability in all phases of development, new routes of drug administration and formulations, pharmacokinetics, pharmacodynamics, bioavailability, and biosimilarity and changes in practice guidelines, standards, policies and regulations are all of interest for publication. Clinical Therapeutics also understands the importance of strengthening the body of publicly accessible evidence surrounding particular agents through the publication of replication studies, negative trials, and failed trials.Beyond therapeutic clinical applications, we seek reports that examine the real-world implications of therapeutics such as comparative effectiveness and pharmacoeconomics studies as well as work that has implications for health policy. Commentaries, which include perspectives and contemporary issues, are sought to offer a balance of viewpoints and scholarly opinion on a broad array of drug-related topics. Case reports, which remain a vital part of our mission, offer clinically valuable lessons. All manuscripts are peer reviewed by independent clinicians or scientists for clinical relevance, technical accuracy, methodological rigor, clarity, and objectivity using a blind review process.In addition to feature articles published monthly, Clinical Therapeutics regularly features a specific theme section dedicated to an annual update of a specific topic area. A special guest editor will comprise each update with reviews, commentaries, and original research highlighting what's new or controversial in the topical specialty. Authors are invited to submit manuscripts for consideration in the topic updates, identifying submissions as such in their cover letters. Submissions not selected for the updates will be considered for general publication. Submit your manuscript at https://www.editorialmanager.com/clinther.Certain manuscript types require prior editorial review before submission to ensure alignment with the journal’s scope and contribution to the field. Authors intending to submit the following types of studies should seek pre-submission approval by contacting the journal office at clinther@elsevier.com with a brief description of the proposed manuscript for editorial evaluation:Adverse event studies based on the FAERS database. Submissions must clearly articulate the novel contribution of the study and how it advances the existing literature. This justification should also be included in the cover letter.Drug–drug interaction studies. Manuscripts must provide a clear methodological rationale for the selection of the agents studied, including clinical or mechanistic justification described within the Methods section.Studies focused on alternative or complementary medicines, including traditional medical systems (e.g., Traditional Chinese Medicine) or supplementation-focused interventions.Out-of-Scope ContentClinical Therapeutics focuses on clinically relevant therapeutic research and studies with clear implications for patient care, therapeutic development, or health policy. The following manuscript categories are generally considered outside the scope of the journal and are not suitable for submission:Animal o

摘自期刊官网 Aims & Scope

研究方向（LetPub）：医学-药学

主编 Jill L. Maron出版商官网

编委会国家分布：未见中国大陆编委；主要国家 美国 20、意大利 7、英国 6、中国香港 2、德国 2（共 46 位编委标注了国家） 编委会 ↗出版商官网 · 2026-10-01

中科院期刊分区表

数据库收录

SCIEScopusLetPub

国际期刊预警名单：各版本均未列入LetPub

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

3.64LetPub · 2026-09-13

影响因子（出版商公布）

3.7出版商官网 · 2026-10-01

CiteScore 2026-06

5.7LetPub · 2026-09-13

CiteScore（出版商公布）

5.7出版商官网 · 2026-10-01

SJR 2026-06

1.04LetPub · 2026-09-13

SNIP 2026-06

1.09LetPub · 2026-09-13

h-index

123LetPub · 2026-09-13

h-index

175OpenAlex · 2026-10-01

i10-index

4,110OpenAlex · 2026-10-01

两年平均被引

2.36OpenAlex · 2026-10-01

自引率

0%LetPub · 2026-09-13

Gold OA 文章占比

24.56%LetPub · 2026-09-13

发文规模

年文章数

163LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

平均审稿速度（社区反馈）

一般,3-8周来源Elsevier官网：平均9周LetPub · 2026-09-13

平均录用比例（社区反馈）

容易LetPub · 2026-09-13

投稿到首次决定

6 天出版商官网 · 2026-10-01

外审后首次决定

61 天出版商官网 · 2026-10-01

投稿到接收

101 天出版商官网 · 2026-10-01

接收到发表

29 天出版商官网 · 2026-10-01

评审方式

单盲同行评审出版商官网

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。

其他费用与减免（作者指南）

版面费

USD 600

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Elsevier Inc.

出版国家或地区

UNITED STATES

出版语言

English

出版周期

Monthly

创刊年份

1977

ISSN

0149-2918

电子版 ISSN

1879-114X

官方链接

• 期刊主页 ↗OpenAlex
• 投稿系统 ↗出版商官网
• 专刊 / 特刊征稿 ↗出版商官网